Moody's: Pfizer's US coronavirus vaccine authorization is credit positive – Reuters

The US-based rating agency Moody’s Investors Service the Food and Drug Administration (FDA) authorization to Pfizer Inc’s coronavirus vaccine is credit positive for the American pharma giant, per Reuters.
Key takeaways
"The approval is credit positive because of incremental profit and cash flow from sales of the vaccine,"
"The revenue and profit opportunities for Pfizer are significant because it has priced the vaccine at a profit."
This comes after the US medical regulator authorized emergency use of the vaccine early Saturday, following the footsteps of the UK and Canada.
Author

Dhwani Mehta
FXStreet
Residing in Mumbai (India), Dhwani is a Senior Analyst and Manager of the Asian session at FXStreet. She has over 10 years of experience in analyzing and covering the global financial markets, with specialization in Forex and commodities markets.

















